Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYing–Hong Shi, Enxiao Li, Weidong Jia et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 39
LRP4 mutations promote tumor progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinomaRongqi Sun, Jian Zhou, Kaixuan Liu et al.|Hepatology|2024Cited by 5